Logo des Robert Koch-InstitutLogo des Robert Koch-Institut
Publikationsserver des Robert Koch-Institutsedoc
de|en
Publikation anzeigen 
  • edoc Startseite
  • Artikel in Fachzeitschriften
  • Artikel in Fachzeitschriften
  • Publikation anzeigen
  • edoc Startseite
  • Artikel in Fachzeitschriften
  • Artikel in Fachzeitschriften
  • Publikation anzeigen
JavaScript is disabled for your browser. Some features of this site may not work without it.
Gesamter edoc-ServerBereiche & SammlungenTitelAutorSchlagwortDiese SammlungTitelAutorSchlagwort
PublizierenEinloggenRegistrierenHilfe
StatistikNutzungsstatistik
Gesamter edoc-ServerBereiche & SammlungenTitelAutorSchlagwortDiese SammlungTitelAutorSchlagwort
PublizierenEinloggenRegistrierenHilfe
StatistikNutzungsstatistik
Publikation anzeigen 
  • edoc Startseite
  • Artikel in Fachzeitschriften
  • Artikel in Fachzeitschriften
  • Publikation anzeigen
  • edoc Startseite
  • Artikel in Fachzeitschriften
  • Artikel in Fachzeitschriften
  • Publikation anzeigen
2011-08-11Zeitschriftenartikel DOI: 10.25646/835
Avian influenza A(H5N1) in humans: new insights from a line list of World Health Organization confirmed cases, September 2006 to August 2010
Fiebig, Lena
Soyka, Jana
Buda, Silke
Buchholz, Udo
Dehnert, Manuel
Haas, Walter
The threat of avian influenza (AI) viruses to humans in Europe in 2005 prompted the Robert Koch Institute to establish a routine monitoring instrument condensing information on all human AI cases worldwide reported from the World Health Organization (WHO) and other sources into a line list for further analysis. The 235 confirmed AI cases captured from September 2006 to August 2010 had a case fatality rate of 56% (132/235), ranging from 28% (27/98) in Egypt to 87% (71/82) in Indonesia. In a multivariable analysis, odds of dying increased by 33% with each day that passed from symptom onset until hospitalisation (OR: 1.33, p=0.002). In relation to children of 0–9 years, odds of fatal outcome were more than six times higher in 10–19 year-olds and 20–29 year-olds (OR: 6.06, 95% CI: 1.89–19.48, p=0.002 and OR: 6.16, 95% CI: 2.05–18.53, p=0.001, respectively), and nearly five times higher in patients of 30 years and older (OR: 4.71, 95% CI: 1.56–14.27, p=0.006) irrespective of the country, which had notified WHO of the cases. The situation in Egypt was special in that case number and incidence in children were more than twice as high as in any other age group or country. With this study, we show that data from the public domain yield important epidemiological information on the global AI situation. This approach to establish a line list is time-consuming but a line list is a prerequisite to such evaluations. We thus would like to encourage the placing of a publicly accessible line list of anonymised human AI cases, e.g. directly by WHO. This might enhance our understanding of AI in humans and permit the rapid detection of changes in its epidemiology with implications for human health.
Dateien zu dieser Publikation
Thumbnail
29pPxVgPEufNc.pdf — PDF — 533.7 Kb
MD5: 12cb43ef759f798779ef6a1d3757cfd8
Zitieren
BibTeX
EndNote
RIS
Keine Lizenzangabe
Zur Langanzeige

Verwandte Publikationen

Anzeige der Publikationen mit ähnlichem Titel, Autor, Urheber und Thema.

  • 2016-02-18Zeitschriftenartikel
    Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case–Control Study, Europe 2014/15 
    Valenciano, Marta; Kissling, Esther; Reuss, Annicka; Rizzo, C.; Gherasim, A.; Horváth, Judit K.; Domegan, L.; Pitigoi, Daniela; Machado, Ausenda; Bella, A.; Paradowska-Stankiewicz, I.; Larrauri, A.; Ferenczi, A.; O´Donell, Joan; Lazar, M.; Pechirra, P.; Korczyńska, M. R.; Pozo, Francisco; Moren, A.
    Influenza A(H3N2), A(H1N1)pdm09 and B viruses co-circulated in Europe in 2014/15. We undertook a multicentre case–control study in eight European countries to measure 2014/15 influenza vaccine effectiveness (VE) against ...
  • 2016-10-13Zeitschriftenartikel
    Improving influenza virological surveillance in Europe: strain-based reporting of antigenic and genetic characterisation data, 11 European countries, influenza season 2013/14 
    Broberg, E.; Hungnes, Olav; Schweiger, Brunhilde; Prosenc, Katarina; Daniels, R.; Guiomar, R.; Ikonen, N.; Kossyvakis, A.; Pozo, Francisco; Puzelli, S.; Thomas, I.; Waters, A.; Wiman, Å.; Meijer, Adam
    Influenza antigenic and genetic characterisation data are crucial for influenza vaccine composition decision making. Previously, aggregate data were reported to the European Centre for Disease Prevention and Control by ...
  • 2013-02-14Zeitschriftenartikel
    Early estimates of seasonal influenza vaccine effectiveness in Europe: results from the i-move multicentre case–control study, 2012/13 
    Valenciano, M.; Kissling, E.
    We conducted a test-negative case–control study based in five European sentinel surveillance networks. The early 2012/13 adjusted influenza vaccine effectiveness was 78.2% (95% CI: 18.0 to 94.2) against influenza B, 62.1% ...
Nutzungsbedingungen Impressum Leitlinien Datenschutzerklärung Kontakt

Das Robert Koch-Institut ist ein Bundesinstitut im

Geschäftsbereich des Bundesministeriums für Gesundheit

© Robert Koch Institut

Alle Rechte vorbehalten, soweit nicht ausdrücklich anders vermerkt.

 
DOI
10.25646/835
Permanent URL
http://dx.doi.org/10.25646/835
HTML
<a href="http://dx.doi.org/10.25646/835">http://dx.doi.org/10.25646/835</a>